09.14.15
Nipro Corp. has agreed to acquire Burlington, Mass.-based Infraredx Inc., an intravascular imaging company focused on coronary artery disease. Nipro’s business includes technology such as artificial organs, circulatory devices, test/diagnostic agents, injection/infusion solutions, ethical pharmaceuticals, and medical glass products.
The acquisition, which is subject to certain conditions, is expected to close by the end of October. No further details of the deal were disclosed.
According to officials from Nipro, the deal combines Nipro's global cardiovascular portfolio and resources along with Infraredx’s industry expertise in near infrared spectroscopy (NIRS) and intravascular ultrasound. The agreement will help introduce Nipro’s cardiovascular product line into the United States.
“Company founder, James E. Muller, M.D., and the Infraredx management team have empowered interventional cardiologists with the NIRS-IVUS imaging system, which is approved to detect the lipid-core plaques that cause most heart attacks,” said Yoshihiko Sano, president of Nipro. “Nipro and Infraredx share a strong patient centered focus and the combination of the companies’ global portfolio and cardiovascular expertise will help us deliver the most comprehensive imaging solution available to change how cardiovascular disease is managed. We look forward to bringing together the two companies to deliver the best of medicine and innovation.”
“By teaming up with one of the leading global medical equipment manufacturing companies in the world, Infraredx is able to leverage Nipro’s global network and vast resources to enhance its presence and impact a larger audience locally as well globally,” said Jason Bottiglieri, president and CEO of Infraredx. “We are pleased to combine our strengths to meet the demands of the marketplace and continue to deliver to the medical community cardiovascular imaging systems that hold the potential to revolutionize the management of cardiovascular disease.”
Founded in 1999, Infraredx is a privately funded medical device company.
Nipro, headquartered in Osaka, Japan, manufacturers medical products as well as provides manufacturing support to other medical device firms. The company’s U.S. base is in Bridgewater, N.J.
The acquisition, which is subject to certain conditions, is expected to close by the end of October. No further details of the deal were disclosed.
According to officials from Nipro, the deal combines Nipro's global cardiovascular portfolio and resources along with Infraredx’s industry expertise in near infrared spectroscopy (NIRS) and intravascular ultrasound. The agreement will help introduce Nipro’s cardiovascular product line into the United States.
“Company founder, James E. Muller, M.D., and the Infraredx management team have empowered interventional cardiologists with the NIRS-IVUS imaging system, which is approved to detect the lipid-core plaques that cause most heart attacks,” said Yoshihiko Sano, president of Nipro. “Nipro and Infraredx share a strong patient centered focus and the combination of the companies’ global portfolio and cardiovascular expertise will help us deliver the most comprehensive imaging solution available to change how cardiovascular disease is managed. We look forward to bringing together the two companies to deliver the best of medicine and innovation.”
“By teaming up with one of the leading global medical equipment manufacturing companies in the world, Infraredx is able to leverage Nipro’s global network and vast resources to enhance its presence and impact a larger audience locally as well globally,” said Jason Bottiglieri, president and CEO of Infraredx. “We are pleased to combine our strengths to meet the demands of the marketplace and continue to deliver to the medical community cardiovascular imaging systems that hold the potential to revolutionize the management of cardiovascular disease.”
Founded in 1999, Infraredx is a privately funded medical device company.
Nipro, headquartered in Osaka, Japan, manufacturers medical products as well as provides manufacturing support to other medical device firms. The company’s U.S. base is in Bridgewater, N.J.